Abstract library

65 results for "chronic atrophic gastritis (CAG)".
#263 Chronic Atrophic Gastritis Associated with Hyperparathyroidism: A prospective Study
Introduction: The association of gastric carcinoids (GCs) type 1 and hyperparathyroidism (HPTH) has been reported, whereas a possible association between chronic atrophic gastritis (CAG) and HPTH is still scant.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Sara Massironi
#621 Occurrence of Type 1 Gastric Carcinoid In Patients with Autoimmune Chronic Atrophic Gastritis
Introduction: The actual incidence of type1 gastric carcinoids (GC1) as a long-term complication of chronic autoimmune atrophic gastritis (CAAG) remains to be clarified as studies are few.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Dr Roberta E Rossi
#818 Treatment with Somatostatin Analogs of Recurrent Type I Gastric Carcinoid in Patients with Autoimmune Chronic Atrophic Gastritis
Introduction: The treatment of type 1 gastric carcinoids (GC1) is still debated, in view of their usual benign behavior.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: PhD Sara Massironi
#1289 Reduced 25-OH-Vitamin D Levels in Patients with Chronic Autoimmune Atrophic Gastritis
Introduction: Chronic atrophic autoimmune gastritis (CAAG) is characterized by parietal cells disruption leading to hypochlorhydria and vitamin B12 malabsorption. An increased risk of osteoporosis was reported in patients with long-standing hypochlorhydria. Only few studies reported a possible association between CAAG and 25OHVitamin D (25OHvitD) deficiency.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: dr Sara Massironi
Keywords: vitamin D, CAAG
#1339 Netazepide, a Gastrin/CCK2 Receptor Antagonist, Can Eradicate Gastric Neuroendocrine Tumours in Patients with Autoimmune Chronic Atrophic Gastritis
Introduction: In a two-centre, 12-week, open trial in 16 patients with chronic atrophic gastritis, hypergastrinaemia, multiple gastric NETs, and raised circulating CgA, the gastrin/CCK2 receptor antagonist, netazepide, reduced the tumour number and size, and normalised CgA.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Malcolm Boyce
Keywords: Netazepide
#267 Plasma Somatostatin: Gastrin Ratio Improves the Diagnosis of Gastrinoma
Introduction: Fasting gastrin alone is inadequate for diagnosis of gastrinoma. Diagnosis requires confirmation of low gastric pH. Low gastric pH is associated with increased numbers of D (somatostatin) cells.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Radha Ramachandran
#18 Long-acting release octreotide induce complete response in type 1 gastric carcinoid tumors
Introduction: Gastric endocrine tumors (GET) are increasingly recognized due to expanding indications of upper gastrointestinal endoscopy. Often silent and benign, GET may also be aggressive when sporadic and may sometimes mimic the course of gastric adenocarcinoma. Current incidence of GETs is estimated at around 8% of digestive endocrine tumors. Yearly age-adjusted incidence is around 0.2 per population of 100,000. Gastric carcinoids (ECLomas) develop from gastric enterochromaffin-like cells (ECL cells) in response to chronically elevated gastrin. Type 1 tumors (ECLomas in the course of atrophic gastritis) may occur in conditions of achlorhydria secondary to auto-immune atrophic fundic gastritis. It occurs mostly in women and they are non-functioning tumors, typically found during upper GI endoscopy performed for dyspepsia. ECLomas present frequently as multiple polyps, usually < 1 cm in diameter in the gastric fundus. Type 1 tumors are almost exclusively benign lesions with little risk of deep invasion of the gastric parietal wall. The neoplastic ECL cells become progressively dedifferentiated with an increasing number of Ki-67 immunoreactive (IR) cell nuclei. In addition, there is a substantial decrease in argynophil and IR NE cells that can be visualized by conventional methods. ECLomas secondary to hypergastrinemia should be closely followed for signs of clinical and histopathological tumor progression. Such ECLomas deserve early, active, radical surgical treatment.
Traditionally, gastric carcinoid type 1 (GCA1s) are endoscopically or surgically removed, depending on the number, appearance and size of the tumors. Antrectomy, with surgical excision of the majority of the G cells, is thought to facilitate regression of these tumors by removing the source of excessive gastrin secretion; however, the long-term benefits of antrectomy still remain uncertain. Although proton pump inhibitors are effective in reducing hypergastrinemia-induced gastric acid hypersecretion in GCA2, they do not affect ECL-cell hyperplasia, and therefore their role in GCA1 is limited. Moreover, in selected cases, significant reduction of hypergastrinemia does not prevent development of ECL carcinoid, suggesting that, in addition to hypergastrinemia, other pathogenic or genetic factors may be involved. Treatment with somatostatin analogues (SSA) might impede ECL-cell hyperplasia by suppressing gastrin secretion and/or by a direct anti-proliferative effect on ECL cells. Treatment with SSAs in GCA1 leads to a substantial tumor load reduction, with a concomitant decrease of serum gastrin levels. Published data indicate an important anti-proliferative effect of SSA on ECL cells, providing clinical benefit and obviating, at least temporarily, the need for invasive therapies for GCA1. Morphometric studies demonstrated that, while antrectomy specifically decreased the volume of ECL cells versus the total volume of endocrine cells, octreotide reduces the overall endocrine cell volume. Although the number of treated patients is small, it has been suggested that SSA may exert important anti-proliferative effects either directly, by inhibiting ECL-cells proliferation, or indirectly through suppression of gastrin hypersecretion.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Ricardo Caponero
#295 Unusual Behavior of Gastric Carcinoid Type 1
Introduction: Gastric carcinoids (GC) are rare tumors of the stomach. GC type 1 are associated with chronic atrophic gastritis (CAG) and are the most benign type, having low metastatic potential.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Matilde P Spampatti
#406 YF476, a Gastrin Receptor Antagonist, Causes Regression of Tumors and Normalizes Serum Chromogranin A in Patients with Type 1 Gastric Carcinoids
Introduction: Chronic atrophic gastritis (CAG) results in achlorhydria, hypergastrinemia and, in some patients, gastric carcinoids (type 1 GCs). Type 1 GCs may become malignant and metastasize. Current treatments of type 1 GCs, such as polypectomy, somatostatin analogues and antrectomy, have their disadvantages. YF476 – a potent, selective, orally active and well-tolerated gastrin receptor antagonist in pre-clinical studies – prevented, as well as reduced, the number and size of gastric carcinoids and carcinomas in rodent models.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Reidar Fossmark
#1069 Gastric Neuroendocrine Neoplasms and Long-Term Proton Pump Inhibitors: Need for a Revision of Classifications?
Introduction: Gastric neuroendocrine neoplasm (gNENs) include three types: type 1 and 2 related to hypergastrinemia due to chronic atrophic gastritis(CAG) or Zollinger-Ellison syndrome (ZES) respectively, and type 3 normogastrinemic and more aggressive. Few cases of gNENs in patients taking proton pump inhibitors (PPI) have been reported
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Federica Cavalcoli
Keywords: PPI, gNEN, classification, CAG